125 related articles for article (PubMed ID: 21815777)
41. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
42. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
[TBL] [Abstract][Full Text] [Related]
43. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
44. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
Seo JY; Hong J; Chun K; Jeong J; Cho H; Kim KH; Park J; Ahn JY; Park PW; Lee JH
Leuk Lymphoma; 2017 Feb; 58(2):357-365. PubMed ID: 27282995
[TBL] [Abstract][Full Text] [Related]
46. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
[TBL] [Abstract][Full Text] [Related]
47. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
49. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
50. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
Paik JH; Go H; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2013 Sep; 54(9):1934-41. PubMed ID: 23327292
[TBL] [Abstract][Full Text] [Related]
52. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
55. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era.
Provencio M; Martín P; García V; Candia A; Sánchez AC; Bellas C
Leuk Lymphoma; 2010 Nov; 51(11):2021-30. PubMed ID: 20919853
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia.
Fujiwara H; Arima N; Ohtsubo H; Matsumoto T; Kukita T; Kawada H; Imaizumi R; Ozaki A; Matsushita K; Tei C
Am J Hematol; 2002 Oct; 71(2):80-4. PubMed ID: 12353304
[TBL] [Abstract][Full Text] [Related]
57. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
58. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.
Rovira J; Valera A; Colomo L; Setoain X; Rodríguez S; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Gaya A; Martínez D; Martínez A; Campo E; López-Guillermo A
Ann Hematol; 2015 May; 94(5):803-12. PubMed ID: 25501975
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
60. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]